Space is undergoing a revolution in access and attainability and may soon cease to be a distant frontier visited only by the select few. The past several years have brought about dozens of milestones in civilian space travel. In 2021 alone, a film crew visited the ISS, Blue Origin and Virgin Galactic completed successful suborbital trips and the first crewed orbital mission without astronauts was achieved.
DUBLIN--(BUSINESS WIRE)--The "Stem Cell Therapy Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering. The global stem cell therapy market reached a value of nearly $4,019.6 million in 2021, having increased at a compound annual growth rate (CAGR) of 70.9% since 2016. The market is expected to grow from $4,019.6 million in 2021 to $10,600.2 million in 2026 at a rate of 21.4%
image:Microglia (in green) in a sea of different excitatory neuron types (colored red or blue). A new study shows how microglia are prompted to change their state to adapt to different areas of the brain. view more Credit: Arlotta Lab From everyday actions like walking and talking to feats of athletic or academic excellence, the brain is constantly acquiring and seamlessly processing information to produce these incredible behaviors.
Medium recently highlighted University of Cincinnati research thatshows early indications that light can be used as a treatment for certain diseases, including cancer. Jiajie Diao, PhD,associate professor in the Department of Cancer Biology in UCs College of Medicine and a University of Cincinnati Cancer Center member, and colleagues at the University of Illinois Urbana-Champaign and the University at Buffalo published the results of their study demonstrating light-activated proteins can help normalize dysfunction within cells in the journal Nature Communications July 25. The researchers attached two separate proteins to mitochondria and lysosomes within stem cells. When stimulated by blue light, the proteins naturally bind to each other to form one new protein, which also brings the mitochondria and lysosome into contact. Once they are brought together, the lysosome can cut the mitochondria, achieving fission
A team at the University of California, Irvine, has identified a signaling molecule that potently stimulates hair growth. A signaling molecule known as SCUBE3, which was discovered by researchers at the University of California, Irvine, has the potential to cure androgenetic alopecia, a prevalent type of hair loss in both women and men. The research, which was recently published in the journal Developmental Cell, uncovered the precise mechanism by which the dermal papilla cells, specialized signal-producing fibroblasts found at the bottom of each hair follicle, encourage new development. Although the critical role dermal papilla cells play in regulating hair growth is widely established, the genetic basis of the activating chemicals involved is little understood. There is a strong need for new, effective hair loss medicines, and naturally occurring compounds that are normally used by the dermal papilla cells present ideal next-generation candidates for treatment, says Maksim Plikus, Ph.D., UCI professor of developmental and cell biology and the studys corresponding author
Panacell believes stem cell therapy could be effective against long COVID Published: Aug 11, 2022 By Mark Terry BioSpace South Korean biotech company Panacell Biotechbelievesit has a way totreat long COVID. Panacell is a research institute specializing in regenerative cell therapies using adipose-derived stem cells (ADSC). It plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat long COVID. Long COVID, which goes by theofficial nameof post-acute sequelae of SARS-CoV-2 infection (PASC), is defined by a broad range of symptoms that persist at least four weeks after infection. According to the Mayo Clinic, one in four people aged 65 or older suffers from the aftereffects of COVID-19
Friday, August 12, 2022 A Purdue University chemical engineer has improved upon traditional methods to produce off-the-shelf human immune cells that show strong antitumor activity, according to a paper published in the peer-reviewed journal Cell Reports. And future research plans include clinical trials involving the Purdue University College of Veterinary Medicine. Dr
The discovery of how to shift damaged brain cells from a diseased state into a healthy one poses a new potential path to treating Alzheimers and other forms of dementia, according to a new collaborative study from researchers at UC San Francisco and Weill Cornell Medicine. The research focuses on microglia, cells that stabilize the brain by clearing out damaged neurons and the protein plaques often associated with dementia and other brain diseases. These cells are understudied, despite the fact that changes in them are known to play a significant role Alzheimer's and other brains diseases, said Dr. Martin Kampmann, associate professor at the Institute for Neurodegenerative Diseases in the UCSF Weill Institute for Neurosciences and co-senior author on the study, which appears Aug.
My debut novel, The Awoken, is a different kind of science fiction in that it is actually about an absence of science. Despite the story being set a century into our future, most scientific and medical innovation has been halted, and in some cases even made illegal.
Tisagenlecleucel boosted survival rates in children with B-cell lymphoblastic leukemia. Further research will be planned to examine the data and analyze additional clinical variables. Higher doses of tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, displayed better survival rates at 1 year for young patients compared with patients who received lower doses who have B-cell lymphoblastic leukemia (B-ALL). Doses remained within the FDA-approved dosing range.1 In the past, we did not have data to guide clinical decisions around commercial CAR T-cell dosing and didnt know if higher doses would affect toxicity and compromise outcomes, or support enhanced anti-leukemia effect, said Liora Schultz, MD, pediatric oncologist at the Stanford Children's Health, Lucile Packard Children's Hospital, and the studys lead author. This data has direct clinical applicability, as it supports use of higher dosing, as available, within the approved tisagenlecleucel dose range
Recent Comments